The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

Publisher： Karger

E-ISSN： 1423-0232|86|1|16-21

ISSN： 0030-2414

Source： Oncology, Vol.86, Iss.1, 2013-12, pp. : 16-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiotoxicity Related to Long‐Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors

By  

THE BREAST JOURNAL, Vol. 21, Iss. 3, 2015-05 ,pp. : 318-321

John Wiley & Sons Inc

Access to resources Recommend Favorite

The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer

By  

Reviews on Recent Clinical Trials, Vol. 1, Iss. 3, 2006-09 ,pp. : 207-215

Bentham Science Publishers

Access to resources Recommend Favorite

Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 14-21

Karger

Access to resources Recommend Favorite

Evaluation of a Device for Negative Selection of CD34+ Cells Alone or in Combination with Breast Cancer Tumor Cell Purging

By  

Transfusion Medicine and Hemotherapy, Vol. 28, Iss. 2, 2001-04 ,pp. : 67-72

Karger

Access to resources Recommend Favorite

The treatment of brain metastasis from breast cancer, role of blood––brain barrier disruption and early experience with trastuzumab

By Tyson Rose Marie   Kraemer Dale F   Hunt Matthew A   Muldoon Leslie L   Orbay Peter   Maron Leeza   Jahnke Kristoph   Neuwelt Edward A  

Therapy, Vol. 3, Iss. 1, 2006-01 ,pp. : 97-112

Future Medicine

Access to resources Recommend Favorite